China Guangzhou-based KingCreate Biotech closes RMB tens of millions Series C financing led by Peakview Capital and followed by Aurora Private Equity and previous investor Legend Capital.
Founded in 2016, KingCreate Biotech is a multi-platform innovative IVD company focusing on infection and oncology. Based on its leading PCR and NGS platforms, the company has launched a wide range of speciality assays for infection and oncology, providing comprehensive precision medicine solutions for customers in China and around the world.
KingCreate Biotech will focus on molecular diagnostic products represented by NGS, and provide hospitals with automated, cost-effective, and accessible molecular diagnostic integrated solutions, according to Zhaohui Hu, Chairman of KingCreate Biotech.
KingCreate Biotech will continue to improve the molecular diagnostic product line of pathogenic microorganisms, strengthen the R&D and innovation capacity of individualised treatment of tumors and genetic diseases, and provide hospitals with more compliant molecular diagnostic products by closely focusing on the clinical needs.
The Post is Available in: English – 简体中文
English (UK) 
简体中文 
Deutsch 
Français 
Español 
Português 
日本語 
Italiano 
Nederlands 
